Many clinical trials have proved the specific renoprotective effect of RAS inhibition by ACE inhibitor/ARB for patients with diabetic or proteinuric non-diabetic CKD to reduce disease progression and mortality51, 52, 53. This evidence concerns the gene ACE and chronic kidney disease.